For patients who undergo pretreatment, eligibility will be determined from pretreatment clinical staging (or final pathologic staging if patient is up-staged). NP and NN patients must ultimately complete standard of care chemotherapy treatment per the National Comprehensive Cancer Network (NCCN) guidelines (Appendix E). NN patients with ER/PR-negative tumors must undergo chemotherapy as dictated by standard of care for inclusion. NN patients in whom chemotherapy is not administered will not be eligible for enrollment. A research nurse coordinator and/or study coordinator will approach these patients about being in the trial and will introduce the trial to the prospective volunteer. If the volunteer is interested and appears eligible, the nurse will arrange an appointment to counsel the patient. The nurse will thoroughly screen the patient for inclusion and exclusion eligibility criteria. If the patient remains interested and eligible, informed consent will be obtained. This screening process may begin prior to the patient completing their standard of care therapy. Written informed consent will be obtained from all study participants. Prospective participants will be provided with a copy of the consent form to read. The research nurse coordinator and/or study coordinator, or Principal Investigator (PI), will explain the study and review the consent form with the patient. Patients will be given ample time to ask and have all questions answered prior to signing the consent form. CONFIDENTIAL Page 23 of 102 Protocol: HERCEPTIN® + E75/GM-CSF Version 3.1 ML25749 05 March 2017 Once written informed consent is obtained, the patient will be HLA-typed. They will be asked for 6-8 cc of blood for HLA-A2/A3/A24/A26 screening (FACS analysis performed in the Cancer Vaccine Development Laboratory [CVDL], Department of Surgery, Uniformed Services University of the Health Sciences [USUHS], Bethesda, MD. Alternatively, the analysis will be performed at M.D.